Overland ADCT BioPharma, a joint venture of Overland Pharmaceuticals and ADC Therapeutics (ADCT), announced that the China National Medical Products Administration (NMPA) has accepted the Biologics License Application for ZYNLONTA, which is seeking an indication for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy in China. The BLA has been granted priority review by the NMPA. The application was made based on the positive results from OL-ADCT-402-001, a Phase 2 bridging clinical trial for ZYNLONTA. The study was designed to evaluate the efficacy and safety of ZYNLONTA as a single-agent treatment for Chinese patients with r/r DLBCL.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ADCT:
- Overland ADCT BioPharma Announces NMPA Accepts Biologics License Application and Grants Priority Review for ZYNLONTA® for Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
- ADC Therapeutics to discontinue LOTIS-9 clinical trial
- ADC Therapeutics price target lowered to $2 from $5 at Morgan Stanley
- ADC Therapeutics announces pause of enrollment in Phase 2 LOTIS-9 trial
- ADC Therapeutics Announces Voluntary Pause of Enrollment in the Phase 2 LOTIS-9 Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) and Rituximab in Unfit or Frail Previously Untreated DLBCL Patients